Dan Calvo Appointed CEO of Gyros AB
News Oct 24, 2013
Gyros AB has announced that Erik Walldén will step down as chief executive officer and president and be replaced by Dan Calvo. Both changes will be effective immediately.
Erik Walldén joined Gyros in 2009. Under his leadership Gyros has successfully established itself as a leader in nano-scale immunoassays, and its technology is increasingly adopted as a standard analytical platform in the biopharmaceutical industry.
Over 150 Gyrolab xP are now installed worldwide with industry leaders, generating over 2.5 million data points on an annual basis.
The Gyrolab system has become a standard analytical platform in pre-clinical research and process development, as well as in later stage clinical studies.
Erik Walldén commented: “Gyros has excellent, robust technology, a talented team of professionals and a sound business foundation. With continued strong commitment by the owners and a new leadership, the company is well geared for the next level of business. It is with pleasure and full confidence I am now handing over to Dan.”
With over 30 years in the life sciences industry, Dan Calvo brings a wealth of leadership experience to Gyros. Previously, as President and CEO of Cellomics he was responsible for leading the company to double-digit growth and positioning the company for sale in 2005 to Fisher Scientific (now Thermo Fisher).
Following his time at Cellomics, Dan was President and CEO of Assay Designs, which was acquired by Enzo Biochem in 2009, and most recently President and CEO of Oncimmune USA LLC, a leading early cancer detection laboratory acquired by Health Diagnostic Laboratory, Inc. Dan has also held executive positions with Perkin Elmer and NEN Life Sciences after a progressive career with DuPont.
Commenting on his appointment, Dan Calvo said: “The Gyros platform has seen increasing uptake by the biopharma and CRO industries globally over the past few years and I am excited to be joining Gyros at this stage of its development. I look forward to steering the company towards the next stage of growth.”
Lars Eric Utterman, Chairman of the Board, commented: “We welcome Dan to Gyros, and look forward to working with him to build on the company’s current strength and reputation. On behalf of Gyros’ board of directors, I would also like to take this opportunity to thank Erik, and wish him success in his next endeavors.”
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Herpesvirus and Alzheimer's Link: High abundance of Herpes genes in postmortem Alzheimer's brain tissueNews
Data from three different brain banks to suggest that human herpesviruses are more abundant in the brains of Alzheimer's patients and may play a role in regulatory genetic networks that are believed to lead to the disease.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE